Loading...
The adrenergic receptor agonist, clonidine, potentiates the anti-parkinsonian action of the selective κ-opioid receptor agonist, enadoline, in the monoamine-depleted rat
1. The treatment of Parkinson's disease relies predominantly upon dopamine replacement therapy, usually with l-dihydroxyphenylalanine (L-DOPA). However, side-effects of long-term treatment, such as L-DOPA-induced dyskinesias can be more debilitating than the disease itself. Non-dopaminergic tre...
Na minha lista:
| Main Authors: | , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
1999
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1571785/ https://ncbi.nlm.nih.gov/pubmed/10602339 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjp.0702943 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|